For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy.
This book deals with the essential factors in the personalization of treatment for primary breast cancer.
This book offers comprehensive coverage of the various aspects of personalized medicine as an original approach to classifying, understanding, treating and preventing disease based on individual biological differences.
To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009.
Tools such as sidebars, key concept summaries, a glossary, and acronym and abbreviation definitions make this book highly accessible to researchers from several fields associated with cancer genomics.
With an understanding of the heterogeneity of breast cancer, patients with luminal or HER2 breast cancer have more specific treatment options other than traditional chemotherapy, the standard therapy for triple-negative breast cancer (TNBC) ...
HER2/neu and Brain Metastasis The overall risk of brain metastasis in patients with advanced breast cancer is 10–15%. This estimate is largely based on the rate of symptomatic brain metastasis, but up to 30% involvement has been ...
This book presents the state of the art of biostatistical methods and their applications in clinical oncology.
This book offers an overview of the main questions arising when biomedical decision-making intersects ethical decision-making. It reports on two ethical decision-making methodologies, one addressing the patients, the other physicians.
This book is intended as a core textbook for courses in public health that examines current issues in health from a social and behavioral science perspective.